NSE: RUBICON | BSE: 544578

Download real time

661.90 -0.80 (-0.12%)

9,712 NSE+BSE Volume

NSE 31 Dec, 2025 10:11 AM (IST)

10,904.8

Market Cap

High in industry

Rubicon Research Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for RUBICON, BSE:544578 Rubicon Research Ltd.

Search Inside the pdf :

Rubicon Research Ltd.

18 Nov 2025

661.90

-0.12%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research Ltd. has an average target of 780.00 from 5 brokers.

Rubicon Research Ltd.

13 Nov 2025

661.90

-0.12%

Outperformance across metrics; stellar start to the post-IPO phase

Buy: Rubicon Research Ltd.

Target

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research Ltd. has an average target of 780.00 from 5 brokers.

Rubicon Research Ltd.

13 Nov 2025

661.90

-0.12%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 36.47% in the last 1 Year

Rubicon Research Ltd.

13 Nov 2025

661.90

-0.12%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research Ltd. is trading above all available SMAs

Rubicon Research Ltd.

13 Nov 2025

661.90

-0.12%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 36.47% in the last 1 Year

Rubicon Research Ltd.

13 Nov 2025

661.90

-0.12%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research has gained 36.47% in the last 1 Year

Rubicon Research Ltd.

13 Nov 2025

661.90

-0.12%

Outperformance across metrics; stellar start to the post-IPO phase

ipo note: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research (Rubicon) delivered better-than-expected performance, with a 7%/18%/21% beat on revenue/EBITDA/PAT for the quarter.

Rubicon Research Ltd. has an average target of 780.00 from 5 brokers.

Rubicon Research Ltd.

31 Oct 2025, 12:00AM

661.90

-0.12%

Gains in the gale

Buy: Rubicon Research Ltd.

Motilal Oswal

Rubicon Research is a fast-growing research and development-driven pharmaceutical manufacturing company with a focus on regulated markets (particularly the US).

Rubicon Research has gained 36.47% in the last 1 Year

Rubicon Research Ltd.

09 Oct 2025

661.90

-0.12%

RUBICON RESEARCH INDIA LIMITED

IPO Subscribe: Rubicon Research Ltd.

Hem Securities

Company is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. Based on the peer set (of seven listed Indian companies assessed by F&S, and Company), company is the only Indian pharmaceutical player with a complete focus on regulated markets. Between Fiscals 2023 and 2025, company was...

Rubicon Research Ltd. has an average target of 780.00 from 5 brokers.

Rubicon Research Ltd.

09 Oct 2025

661.90

-0.12%

Rubicon Research : IPO

IPO Note: Rubicon Research Ltd.

ICICI Direct

Rubicon is one of the fastest growing Indian pharmaceutical companies focusing completely on the US market which contributed ~99% of the FY25 revenues. It has a pipeline of 17 products under review with the USFDA and...